
Its rating is now a buy with a new discounted cashflow-derived target price of RM4 from RM3.30, which is at a 2% yield.
PETALING JAYA: Duopharma Biotech Bhd has been upgraded to a buy from a sell by RHB Research, given the increased clarity on its chances to participate in vaccine rolloutss in the country.
The research house also noted that its human insulin contract had also been extended.
Save 30% for ads-free and full access now!
